Trial Profile
A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Vosaroxin (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 23 Mar 2022 Planned End Date changed from 31 Dec 2021 to 29 Apr 2024.
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 23 Jun 2017 Results published in a Sunesis Pharmaceuticals media release.